Article
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
The Prostate - 1 May 2022
Antonarakis Emmanuel S, Tierno Marni, Fisher Virginia, Tukachinsky Hanna, Alexander Sonja, Hamdani Omar, Hiemenz Matthew C, Huang Richard S P, Oxnard Geoffrey R, Graf Ryon P
Abstract excerpt
BACKGROUND: Liquid biopsy is a powerful tool that can enable treatment decisions for metastatic prostate cancer patients with difficult-to-biopsy tumors. However, the detection of genomic alterations via liquid biopsy is limited by the fraction (tumor fraction [TF]) of circulating tumor DNA (ctDNA) within the total cell-free DNA content. While prior work has preliminarily correlated TF with clinical features of...
Topics
Join the communities discussing this publication.